New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
08:36 EDTDXRHeart failure study from Mayo Clinic using Daxor's BVA-100 published
The Journal of the American College of Cardiology - Heart Failure has published the first study measuring congestive heart failure patients' blood volumes at the initiation of treatment and just prior to discharge. This study involved 26 Class III/IV cardiac patients who are usually treated without blood volume measurements on the basis of clinical evaluations and tests such as hematocrits/hemoglobins, which measure the ratio of a patient's red cells but not the actual volume of a patient's blood. Retention of sodium and water and expansion of a patient's blood volume are the most fundamental derangements which occur in congestive heart failure patients. Total blood volume analysis demonstrates a wide range in the extent of volume overload. 24 out of 26 patients were hypervolemic, with a range of up 9.5%-107% above the normal volume. By measuring blood volume at discharge, it was possible to compute whether the fluids removed were from the blood volume itself or from the interstitial fluid, which is the body fluid surrounding the cells of the body. On average 85% of the fluid removed came from the interstitial space. However, there was a wide range of variability within the patient population. The authors also noted that at discharge, despite vigorous therapy, most of the patients still had abnormally expanded blood volumes. The authors noted "The extent of composition and distribution of volume overload are highly variable in decompensated congestive heart failure and this variability needs to be taken into account in the approach to individualized therapy. The authors further noted that "Utilizing current methods, the accurate assessment and management of volume overload in patients with decompensated heart failure remains problematic".
News For DXR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 17, 2015
13:01 EDTDXRDaxor announces patent approval, update on buyback program
Daxor announced the approval of a patent and an update on its stock buyback program. Daxor said has received notification from the U.S. Patent Office that its patents for the total body albumin analyzer and its supplementary patent on its Blood Volume Analyzer filed on October 25, 2011, have been approved. The actual patent is expected to be issued within the next 30 to 60 days. The patents for the total body albumin analyzer are the first patents ever issued for an instrument to measure the total albumin within the human body, the company said. On March 16th, the company repurchased 44,145 shares of its common stock. The total amount of shares held by insiders and institutional investors as of March 17 is 3.45M. Of this amount, 3.17M shares are held by insiders and 278,933 shares are held by institutional investors. The company has in place a program which allows it to repurchase up to 250K shares each year. Since January 1, the company has repurchased 84,627 shares of its common stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use